Briacell Therap (NASDAQ:BCTX) Sees Significant Decline in Short Interest

Briacell Therap (NASDAQ:BCTX) saw a significant decrease in short interest in the month of August. As of August 31st, there was short interest totaling 23,200 shares, a decrease of 33.9% from the August 15th total of 35,100 shares. Based on an average daily trading volume, of 124,900 shares, the short-interest ratio is presently 0.2 days. Approximately 1.4% of the company’s stock are short sold. Approximately 1.4% of the company’s stock are short sold. Based on an average daily trading volume, of 124,900 shares, the short-interest ratio is presently 0.2 days.

Briacell Therap Stock Performance

Shares of BCTX opened at $8.21 on Wednesday. The company has a market capitalization of $5.58 million, a P/E ratio of -0.10 and a beta of 1.18. Briacell Therap has a one year low of $6.00 and a one year high of $214.50. The stock has a 50-day moving average price of $9.14 and a 200 day moving average price of $26.92.

Briacell Therap Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.